315 results on '"Al Zignego"'
Search Results
2. Poster Session 4: Acute Liver Failure and Artificial Liver Support; Diagnostics, Epidemiology, and Natural History
- Author
-
Antonio Gasbarrini, Francesco Russo, Liliana Chemello, Teresa Santantonio, Luchino Chessa, Paolo Caraceni, M. Puoti, Al Zignego, M. Rizzetto, Marco Marzioni, A. Di Leo, Carlo Ferrari, P. Andreone, Stefano Rosato, Pierluigi Blanc, A. Kondili L A Loreta, Me Tosti, Maurizia Rossana Brunetto, L. E. Weimer, G. Raimondo, Michele Quaranta, Raffaele Bruno, Carmine Coppola, Alessandra Mallano, Loredana Falzano, Gabriella Verucchi, Alfredo Alberti, G. Taliani, E.M. Erne, M Massella, Maria Cristina Vinci, Erica Villa, Marcello Persico, Stefano Vella, Giovanna Fattovich, De Rose Agostino Maria, G.B. Gaeta, M. Andreoni, Guglielmo Borgia, and Antonio Craxì
- Subjects
Prioritization ,Pediatrics ,medicine.medical_specialty ,Life evaluation ,Hepatology ,CpG site ,business.industry ,Cohort ,Medicine ,business ,Studio - Published
- 2015
3. Forecasting liver disease burden based on a real life cohort of the linked to care patients in Italy. Does the ‘underwater portion of the iceberg’ matter to reach the WHO HCV eliminating goals in the high HCV prevalent countries?
- Author
-
Angelo Andriulli, M. Strazzabosco, M.G. Rumi, Maurizia Rossana Brunetto, T. Santantonio, Pierluigi Blanc, Ivane Gamkrelidze, E.M. Erne, Gloria Taliani, Sarah Blach, Pietro Lampertico, Luchino Chessa, Massimo Zuin, Carmine Coppola, Al Zignego, Alessandro Federico, Homie Razavi, Marco Massari, Andrea Iannone, Simona Montilla, P. Andreone, S. Robbins, Guglielmo Borgia, D. Ieluzzi, Stefano Vella, Antonio Craxì, Nicola Caporaso, M. Puoti, Alessandro Gasbarrini, A. Ciancio, Mario Melazzini, Maria Cristina Vinci, G. Raimondo, Marcello Persico, C. Ferrari, Loreta A. Kondili, G.B. Gaeta, Francesco Russo, and Andrea Gori
- Subjects
Liver disease ,Hepatology ,business.industry ,Environmental health ,Cohort ,medicine ,medicine.disease ,business ,Iceberg - Published
- 2018
4. Forecasting liver disease burden
- Author
-
T. Santantonio, Massimo Zuin, Maurizia Rossana Brunetto, Angelo Andriulli, Homie Razavi, Stefano Vella, Simona Montilla, S. Madonia, M. Strazzabosco, Nicola Caporaso, S. Robbins, G. Raimondo, Antonio Gasbarrini, P.L. Blanc, Francesco Russo, Andrea Iannone, Guglielmo Borgia, Andrea Gori, Antonio Craxì, D. Ieluzzi, A. Ciancio, Ivane Gamkrelidze, Mario Melazzini, E.M. Erne, Marco Massari, G.B. Gaeta, Luchino Chessa, M.G. Rumi, Gloria Taliani, Al Zignego, P. Andreone, Sarah Blach, M. Puoti, Carmine Coppola, Loreta A. Kondili, Maria Cristina Vinci, Marcello Persico, Alessandro Federico, Carlo Ferrari, and Pietro Lampertico
- Subjects
medicine.medical_specialty ,Liver disease ,Hepatology ,business.industry ,Gastroenterology ,medicine ,Intensive care medicine ,medicine.disease ,business - Published
- 2018
5. P.04.20 LONGITUDINAL EVALUATION OF LIVER FIBROSIS AND OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C UNDERGOING IFN-FREE ANTIVIRAL TREATMENT
- Author
-
Monica Monti, Al Zignego, E. Carradori, Luisa Petraccia, Laura Gragnani, Cristina Stasi, Sinan Sadalla, and Francesco Madia
- Subjects
medicine.medical_specialty ,Hepatology ,Chronic hepatitis ,business.industry ,Internal medicine ,Liver fibrosis ,Gastroenterology ,medicine ,In patient ,Antiviral treatment ,business ,Ifn free - Published
- 2019
6. Extracellular vesicles derived from CHK2 mRNA as a possible predictive marker of HCC in HCV-infected patients
- Author
-
Serena Lorini, Silvia Marri, Laura Gragnani, Al Zignego, V. Carloni, P. Caini, and L. Cavallini
- Subjects
Messenger RNA ,Predictive marker ,Hepatology ,business.industry ,Gastroenterology ,Medicine ,business ,Extracellular vesicles ,Molecular biology - Published
- 2019
7. Mixed cryoglobulinemia patients with persisting symptoms after SVR are characterized by B-cell clonality markers
- Author
-
Adriano M. Pellicelli, A. Xheka, E. Carradori, Al Zignego, L. Martini, L. Cosmi, Monica Monti, Umberto Basile, Silvia Marri, F. Annunziato, Luisa Petraccia, P. Caini, Serena Lorini, Laura Gragnani, Veronica Santarlasci, and Francesco Madia
- Subjects
medicine.anatomical_structure ,Hepatology ,business.industry ,Mixed cryoglobulinemia ,Immunology ,Gastroenterology ,Medicine ,business ,B cell - Published
- 2019
8. GENDER DIFFERENCES IN HCV CHRONIC LIVER DISEASE: A REAL LIFE EVALUATION IN PITER (PIATTAFORMA ITALIANA PER LO STUDIO DELLA TERAPIA DELLE EPATITI VIRALI) COHORT STUDY
- Author
-
M. Puoti, G.B. Gaeta, T. Santantonio, Francesco Paolo Russo, Silvia Fargion, M. Siciliano, M. Di Gregorio, Salvatore Madonia, Pierluigi Toniutto, D. Ieluzzi, Loredana Falzano, Giuseppe Montalto, Luchino Chessa, Giuseppe Foti, Adriano Lazzarin, Gianpiero D'Offizi, Carmine Coppola, Gloria Taliani, Claudio Viscoli, Massimo Zuin, Maria Rendina, Antonio Craxì, Al Zignego, Giovanni Raimondo, V. De Maria, E.M. Erne, Mario Strazzabosco, Adele Giammario, M. Colombo, P. Andreone, Claudio Maria Mastroianni, Alessandro Federico, G. Angarano, Andrea Giacometti, Maria Cristina Vinci, Antonio Benedetti, Carlo Ferrari, Erica Villa, Floriano Rosina, Marcello Persico, G. Nardone, Marco Massari, M. Rumi, Liliana Chemello, Gabriella Verucchi, Ivan Gentile, M.G. Quaranta, Loreta A. Kondili, Guglielmo Borgia, M. Andreoni, Stefano Vella, Antonio Gasbarrini, Maurizia Rossana Brunetto, Pierluigi Blanc, Alessia Ciancio, Alfredo Alberti, Carlo Torti, A. Di Leo, Nicola Caporaso, Kondili, L, Quaranta, Mg, Falzano, L, Di Gregorio, M, Brunetto, M, Zignego, Al, Ciancio, A, Di Leo, A, Rendina, M, Raimondo, G, Ferrari, C, Craxi, A, Taliani, G, Borgia, Guglielmo, Gentile, Ivan, Santantonio, Ta, Giammario, A, Blanc, P, Gaeta, Gb, Gasbarrini, A, Siciliano, M, Chessa, L, Erne, Em, Ieluzzi, D, Russo, Fp, Andreone, P, Vinci, M, Coppola, C, Chemello, L, Madonia, S, Verucchi, G, Persico, M, Zuin, M, Alberti, A, Puoti, M, Nardone, G, De Maria, V, Massari, M, Montalto, G, Foti, G, Rumi, Mg, Giacometti, A, Benedetti, A, D'Offizi, G, Strazzabosco, M, Fargion, S, Angarano, G, Federico, A, Caporaso, Nicola, Mastroianni, C, Toniutto, P, Colombo, M, Lazzarin, A, Torti, C, Andreoni, M, Rosina, F, Viscoli, C, Vella, S, and Villa, E.
- Subjects
030203 arthritis & rheumatology ,medicine.medical_specialty ,Hepatology ,business.industry ,Chronic liver disease ,medicine.disease ,Surgery ,03 medical and health sciences ,0302 clinical medicine ,Life evaluation ,Internal medicine ,medicine ,030211 gastroenterology & hepatology ,business ,Studio ,Cohort study - Published
- 2016
9. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis
- Author
-
Massimo Galli, Antonio Tavoni, Davide Filippini, Al Zignego, Patrizia Scaini, Stefano Bombardieri, Paola Masolini, Clodoveo Ferri, S. Migliaresi, Maria Teresa Mascia, M. Maset, Oreste Perrella, Mauro Campanini, C. Naclerio, M. Pietrogrande, Armando Gabrielli, Pietro Pioltelli, M. Lenzi, Alen Zabotti, S. De Vita, Miriam Isola, Dario Roccatello, Giuseppe Monti, Luca Quartuccio, and Cesare Mazzaro
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Immunology ,Azathioprine ,Birmingham Vasculitis Activity Score ,Hepatitis C ,medicine.disease ,Gastroenterology ,law.invention ,Surgery ,Rheumatology ,Randomized controlled trial ,law ,Internal medicine ,Immunology and Allergy ,Medicine ,Pharmacology (medical) ,Rituximab ,Plasmapheresis ,business ,Vasculitis ,Cryoglobulinemic vasculitis ,medicine.drug - Abstract
Objective To conduct a long-term, prospective, randomized controlled trial evaluating rituximab (RTX) therapy for severe mixed cryoglobulinemia or cryoglobulinemic vasculitis (CV). Methods Fifty-nine patients with CV and related skin ulcers, active glomerulonephritis, or refractory peripheral neuropathy were enrolled. In CV patients who also had hepatitis C virus (HCV) infection, treatment of the HCV infection with antiviral agents had previously failed or was not indicated. Patients were randomized to the non-RTX group (to receive conventional treatment, consisting of 1 of the following 3: glucocorticoids; azathioprine or cyclophosphamide; or plasmapheresis) or the RTX group (to receive 2 infusions of 1 gm each, with a lowering of the glucocorticoid dosage when possible, and with a second course of RTX at relapse). Patients in the non-RTX group who did not respond to treatment could be switched to the RTX group. Study duration was 24 months. Results Survival of treatment at 12 months (i.e., the proportion of patients who continued taking their initial therapy), the primary end point, was statistically higher in the RTX group (64.3% versus 3.5% [P < 0.0001]), as well as at 3 months (92.9% versus 13.8% [P < 0.0001]), 6 months (71.4% versus 3.5% [P < 0.0001]), and 24 months (60.7% versus 3.5% [P < 0.0001]). The Birmingham Vasculitis Activity Score decreased only after treatment with RTX (from a mean ± SD of 11.9 ± 5.4 at baseline to 7.1 ± 5.7 at month 2; P < 0.001) up to month 24 (4.4 ± 4.6; P < 0.0001). RTX appeared to be superior therapy for all 3 target organ manifestations, and it was as effective as conventional therapy. The median duration of response to RTX was 18 months. Overall, RTX treatment was well tolerated. Conclusion RTX monotherapy represents a very good option for severe CV and can be maintained over the long term in most patients.
- Published
- 2012
10. Clinical characterization and economic impact evaluation of anti-HCV DAA treatment failure: real life data from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER)
- Author
-
Luchino Chessa, Emanuela Zappulo, Gloria Taliani, Guglielmo Borgia, Matteo Ruggeri, L Cavalletto, Monica Monti, Al Zignego, L. Donnarumma, Romina Corsini, Filomena Morisco, A. Giammario, F.R. Rolli, P. Andreone, Marzia Margotti, G. Raimondo, Vincenza Calvaruso, V. Rizzo, Alberto Zanetto, Francesco Russo, Stefano Rosato, Roberto Filomia, Maurizia Rossana Brunetto, G.B. Gaeta, D.C. Amoruso, T. Santantonio, S. Madonia, Marco Massari, Elisa Biliotti, B. Del Pin, Mario Masarone, Pierluigi Blanc, Erica Villa, Marcello Persico, Liliana Chemello, A. Di Leo, Loreta A. Kondili, M.G. Rumi, Veronica Bernabucci, S. Petta, Carmine Coppola, Loredana Falzano, M. Siciliano, M.C. Pasetto, D. Ieluzzi, Barbara Coco, Andrea Iannone, and Alessandro Gasbarrini
- Subjects
medicine.medical_specialty ,Hepatology ,Anti hiv ,business.industry ,medicine ,Economic impact analysis ,Intensive care medicine ,Viral hepatitis ,medicine.disease ,business ,Real life data ,Virology ,Treatment failure - Published
- 2017
11. Non-invasive B-cell clonality markers may help in the rational approach to HCV SVR cryoglobulinemic patients with persisting manifestations
- Author
-
Umberto Basile, L. Cosmi, Laura Gragnani, A. Xheka, Al Zignego, Serena Lorini, L. Martini, Veronica Santarlasci, Monica Monti, Francesco Madia, F. Annunziato, E. Carradori, Silvia Marri, Luisa Petraccia, P. Caini, and Adriano M. Pellicelli
- Subjects
medicine.anatomical_structure ,Hepatology ,business.industry ,Non invasive ,Immunology ,Gastroenterology ,medicine ,business ,B cell - Published
- 2018
12. NOTCH4 and MHC class II polymorphisms contibute to HCV-related benign and malignant lymphoproliferative diseases
- Author
-
Laura Gragnani, Elisa Fognani, Massimo Libra, V. De Re, Alessia Piluso, Al Zignego, and A. Genovesi
- Subjects
MHC class II ,Hepatology ,biology ,business.industry ,Immunology ,Gastroenterology ,biology.protein ,Medicine ,business - Published
- 2015
13. High SVR Rates with SMV + SOF in HCV GT1 and GT4 Patients with Cirrhosis or Advanced Fibrosis: A Real Practice Analysis from a Large Regional Database in Tuscany, Italy
- Author
-
Francesco Menichetti, A. De Luca, Silvia Chigiotti, D. Bartolozz, Filippo Oliveri, S. Luchi, Al Zignego, D. Aquilini, Paolo Forte, Cesira Nencioni, Paola Carrai, C. Catalani, Maurizia Rossana Brunetto, Pierluigi Blanc, Laura Gragnani, Piero Colombatto, S. Sani, Elena Salomoni, Rodolfo Sacco, Elena Gianni, and Danilo Tacconi
- Subjects
medicine.medical_specialty ,Pediatrics ,Cirrhosis ,Hepatology ,medicine.diagnostic_test ,business.industry ,Renal function ,medicine.disease ,Gastroenterology ,Advanced fibrosis ,03 medical and health sciences ,Liver disease ,0302 clinical medicine ,Liver stiffness ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,030211 gastroenterology & hepatology ,Stage (cooking) ,Liver function tests ,business - Abstract
s / Digestive and Liver Disease 48S (2016) e1–e17 e5 eGFR was ≥60mL/min/1.73m2 in 92 patients (93.8%) and between45and59mL/min/1.73m2 in6patients (6.1%).Glomerular involvement was found in 19 patients (19.4%), tubular involvement in 31 (31.6%) and they co-occurred in 10 patients (p=0.034). Subjects with glomerular or tubular involvement, or both, showed significantly lower eGFRvalues (p=0.005). AROC curvewasdrafted and a cut point of 90ml/min predicted renal involvement (RI) (sensitivity 63%, specificity 75%), although it was unable to distinguish tubular vs glomerular involvement (p=0.914). Patients with RI were older, had higher ACR and 1MCR levels and exhibited a more severe KDIGO stage. No association was found between RI and: HCV-RNA levels, liver stiffness and liver function tests. L-FABP andKIM-1 levelswere significantlyhigher inpatientswithRI. Tubular involvement was significantly associated with increased levels of L-FABPandKIM-1,while glomerular involvementwas associated only with high L-FABP level. Conclusion: Tubular and/or glomerular involvement are quite frequent in HCV cirrhotic patients. The occurrence of eGFR
- Published
- 2016
14. Sustained virological response in HCV patients treated with daclatasvir + sofosbuvir, with or without ribavirin: a multicenter, field-practice experience
- Author
-
R. Cinelli, Dario Bartolozzi, Giampaolo Bresci, Esperti F, Francesco Mazzotta, Maurizia Rossana Brunetto, Beatrice Valoriani, Al Zignego, Sara Parodi, Elena Gianni, Paolo Forte, R. Gattai, I. Vivaldi, Rachele Puntili, Alessandro Nerli, Cesira Nencioni, Laura Gragnani, Elena Salomoni, Giovanni Andreotti, Barbara Coco, S. Luchi, Rodolfo Sacco, A. De Luca, D. Aquilini, Piero Colombatto, S. Sani, Massimo Pozzi, Loredana Ricciardi, G. Tapete, and Maria Piera Riccardi
- Subjects
medicine.medical_specialty ,Daclatasvir ,Hepatology ,Sofosbuvir ,business.industry ,Ribavirin ,Virology ,Virological response ,chemistry.chemical_compound ,chemistry ,Field practice ,Internal medicine ,medicine ,business ,medicine.drug - Published
- 2017
15. Diagnostic and therapeutic approaches of mixed cryoglobulinemia in PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort
- Author
-
N. Passigato, Luchino Chessa, Al Zignego, Marzia Margotti, M. Andreoni, Elisa Biliotti, Stefano Vella, Romina Corsini, P. Andreone, Liliana Chemello, M. Puoti, M.G. Quaranta, Emanuela Zappulo, Loreta A. Kondili, Gloria Taliani, L. E. Weimer, Elena Danieli, G. Lazzarini, L Cavalletto, Maria Cristina Vinci, Marcello Persico, Alessandro Federico, S. Palladini, Guglielmo Borgia, Marcello Dallio, D. Ieluzzi, Marco Massari, Giuseppe Mazzella, M. Gonzo, Carlotta Cerva, Maurizia Rossana Brunetto, Mario Masarone, M.C. Pasetto, Barbara Coco, V. Sciola, G.B. Gaeta, Alfredo Alberti, V. Rizzo, Monica Monti, S. Madonia, and M.G. Rumi
- Subjects
03 medical and health sciences ,Pediatrics ,medicine.medical_specialty ,0302 clinical medicine ,Hepatology ,business.industry ,030220 oncology & carcinogenesis ,Mixed cryoglobulinemia ,Cohort ,Medicine ,030211 gastroenterology & hepatology ,business ,Studio - Published
- 2017
16. Sofosbuvir/Ribavirin treatment in patients with genotype 2, Hepatitis C Virus infection and symptomatic mixed cryoglobulinemia: an interim analysis on safety, efficacy and impact on quality of life
- Author
-
Massimo Galli, Guia Cerretelli, Al Zignego, Luisa Petraccia, G.B. Gaeta, Gianluca Brancaccio, Elisa Fognani, Salvatore Sollima, Laura Gragnani, Monica Monti, Elena Gianni, and U. Arena
- Subjects
medicine.medical_specialty ,Hepatology ,Sofosbuvir ,business.industry ,Hepatitis C virus ,Ribavirin ,030232 urology & nephrology ,medicine.disease_cause ,Interim analysis ,Virology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Quality of life ,chemistry ,030220 oncology & carcinogenesis ,Internal medicine ,Genotype ,Mixed cryoglobulinemia ,medicine ,In patient ,business ,medicine.drug - Published
- 2017
17. Mixed cryoglobulinaemia: a cross-road between autoimmune and lymphoproliferative disorders
- Author
-
L. La Civita, Giampiero Pasero, Al Zignego, Giovanni Longombardo, and Clodoveo Ferri
- Subjects
030203 arthritis & rheumatology ,business.industry ,Hepatitis C virus ,Autoantibody ,Lymphoproliferative disorders ,Glomerulonephritis ,030204 cardiovascular system & hematology ,medicine.disease_cause ,medicine.disease ,Hepatitis C ,Lymphoproliferative Disorders ,Autoimmune Diseases ,Lymphoma ,03 medical and health sciences ,0302 clinical medicine ,Cryoglobulinemia ,Rheumatology ,Rheumatoid arthritis ,Immunology ,medicine ,Mixed cryoglobulinaemia ,autoimmunity ,lymphoproliferation ,Humans ,business ,Vasculitis ,Systemic vasculitis - Abstract
Mixed cryoglobulinaemia (MC) is a systemic vasculitis, secondary to the deposition in small and medium-sized blood vessels of circulating immune complexes, mainly the cryoglobulins, and complement. MC is characterised by a typical clinical triad (purpura, weakness, arthralgias) and by one or more organ involvement: chronic hepatitis, glomerulonephritis, peripheral neuropathy, skin ulcers and diffuse vasculitis. In a limited number of MC patients, a malignancy, that is B-cell non-Hodgkin's lymphoma or hepatocellular carcinoma, may also develop. Hepatitis C virus (HCV) infection has been found in the majority of patients with MC; the frequency of HCV markers (91%) was significantly higher than other rheumatic diseases (6.4%), namely systemic lupus, Sjùgren's syndrome, rheumatoid arthritis and systemic sclerosis, or healthy controls (1.2%). The HCV infection of lymphoid tissues may represent the remote event leading to B-lymphocyte proliferation responsible for autoantibodies and immune-complex production. In a similar way, HCV infection may also be involved in the pathogenesis of other autoimmune (glomerulonephritis, thyroiditis, lung fibrosis, autoimmune hepatitis, porphyria cutanea tarda) and lymphoproliferative disorders (monoclonal gammopathies, B-cell lymphomas). MC shares numerous clinico-serological and pathological features with the above disorders. HCV seems to be their common etiological agent; however, a variable combination of unknown co-factors (infectious, genetic, environmental) should be determinant for the appearance of different clinical patterns.
- Published
- 1998
18. Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection
- Author
-
G. Careccia, Francesca Giannelli, Carlo Giannini, S Barbagli, Ferruccio Bonino, Maurizia Rossana Brunetto, Monica Monti, R Fontana, G. Buzzelli, S Puliti, Paolo Gentilini, and Al Zignego
- Subjects
Adult ,Male ,Hepatitis C virus ,Interferon alpha-2 ,Biology ,medicine.disease_cause ,Antiviral Agents ,Liver disease ,Virology ,medicine ,Humans ,Hepatitis B Antibodies ,Interferon alfa ,Aged ,Hepatitis B virus ,Interferon-alpha ,virus diseases ,Alanine Transaminase ,General Medicine ,Hepatitis C ,Hepatitis C Antibodies ,Hepatitis C, Chronic ,Middle Aged ,Hepatitis B ,medicine.disease ,biology.organism_classification ,Recombinant Proteins ,digestive system diseases ,Hepadnaviridae ,DNA, Viral ,Immunology ,Coinfection ,RNA, Viral ,Female ,medicine.drug - Abstract
The possibility of hepatitis B virus (HBV) infection in HBsAg-negative patients has been shown. However, an "inapparent" coinfection by HBV in hepatitis C virus (HCV)-positive patients generally is not taken into account in clinical practice. Mechanisms responsible for resistance to interferon (IFN) have not been completely clarified. The aim of this study was to investigate whether an "inapparent" coinfection by HBV in anti-HCV-positive chronic liver disease patients may influence IFN response. Fourteen anti-HCV positive, HBsAg-negative but serum HBV DNA-positive patients by PCR and 111 anti-HCV-positive, HBsAg-negative and HBV DNA (PCR)-negative patients with chronic hepatitis were treated with 3 MU of recombinant alpha-2a IFN 3 times weekly for 12 months. Serum HBV DNA and HCV RNA were determined before treatment, after 6-12 months and in coincidence with ALT flare-up by PCR. HBV PCR was performed using primers specific for the S region of the HBV genome and HCV PCR with primers localised in the 5'NC region of HCV genome. IgM anti-HBc was tested using IMx Core-M Abbott assay. By the end of treatment, ALT values had become normal in 4/14 HBV DNA-positive patients (28%), but all "responders" (4/4) relapsed between 2 and 5 months after therapy. All but one patient were HCV RNA-positive before treatment, 6 were also both HBV DNA and HCV RNA-positive during ALT flare-ups. In 5 patients, only HBV DNA and in 3 patients, only HCV RNA was detected when transaminase values increased. All patients remained HBsAg-negative and anti-HCV-positive. IgM anti-HBc was detected both before treatment and during ALT elevation in 3 patients and only during ALT relapse in 3 others. Of the 111 anti-HCV positive, HBsAg-negative and HBV DNA (PCR)-negative patients with chronic hepatitis, a biochemical response to IFN treatment was observed in 54% of the cases. Relapse of ALT values was observed in 47% of the cases during a follow-up of 1 year after treatment. "Inapparent" HBV/HCV coinfection may be implicated in cases of resistance to IFN treatment. In addition, HBV replication may persist in patients in whom HCV replication was inhibited by IFN treatment. The pathogenic role of HBV in liver disease was confirmed by detection of IgM anti-HBc in some cases; the appearance of these antibodies only after IFN treatment suggests that IFN may exert a selective role in favour of HBV. Further studies will show the effect of different treatment schedules. HBV DNA and/or IgM anti-HBc detection with very sensitive methods may be important both as a prognostic factor and as a tool for better understanding interviral relationships and mechanisms involved in multiple hepatitis virus infections.
- Published
- 1997
19. High circulating chemokines (C-X-C motif) ligand 9, and (C-X-C motif) ligand 11, in hepatitis C-associated cryoglobulinemia
- Author
-
Michele Colaci, Silvia Frascerra, Silvia Martina Ferrari, Domenico Sansonno, Alessandro Antonelli, Andreina Teresa Manfredi, Clodoveo Ferri, Al Zignego, Poupak Fallahi, and Caterina Mancusi
- Subjects
Adult ,Male ,medicine.medical_specialty ,Chemokine ,mixed cryoglobulinemia ,Hepatitis C virus ,Immunology ,medicine.disease_cause ,Chemokine CXCL9 ,stomatognathic system ,Internal medicine ,parasitic diseases ,medicine ,Humans ,Immunology and Allergy ,CXCL11 ,Aged ,Aged, 80 and over ,Pharmacology ,biology ,Chemistry ,HEPATITIS C VIRUS ,Chemotaxis ,Hepatitis C ,Middle Aged ,cxcl9 ,medicine.disease ,Cryoglobulinemia ,Chemokine CXCL11 ,stomatognathic diseases ,Endocrinology ,biology.protein ,CXCL9 ,Female ,Vasculitis - Abstract
(C-X-C motif) ligand 9 and (C-X-C motif) ligand 11 (CXCL9 and CXCL11), are potent chemoattractants for activated T cells, and play an important role in T helper 1 (Th)1 cell recruitment in chronic hepatitis C. No study has evaluated CXCL9, together with CXCL11, circulating levels in patients with mixed cryoglobulinemia and hepatitis C (MC+HCV-p). The aim of the present study therefore was to measure serum CXCL9, and CXCL11 levels, in MC+HCV-p, and to relate the findings to the clinical phenotype. Serum CXCL9 and CXCL11 were measured in 71 MC+HCV-p and in matched controls. MC+HCV-p showed significantly higher mean CXCL9 and CXCL11 levels than controls (P less than 0.001, for both), in particular, in 32 patients with active vasculitis (P less than 0.001). By defining high CXCL9 or CXCL11 level as a value of at least 2 SD above the mean value of the control group ( greater than 100 pg/mL): 89 percent MC+HCV-p and 5 percent controls had high CXCL9 (P less than 0.0001, chi-square); 90 percent MC+HCV-p and 6 percent controls had high CXCL11 (P less than 0.0001, chi-square). In a multiple linear regression model of CXCL9 vs age, ALT, CXCL11, only CXCL11 was significantly (r = 0.452, P less than 0.0001) and independently related to CXCL9. Our study demonstrates in MC+HCV-p vs controls: (i) high serum CXCL9, and CXCL11, significantly associated with the presence of active vasculitis; (ii) a strong relationship between circulating CXCL9 and CXCL11. Future studies on a larger cohort of patients are needed to evaluate the relevance of serum CXCL9 and CXCL11 determination as clinico-prognostic marker of MC+HCV.
- Published
- 2013
20. High SVR rates with SMV+SOF in HCV GT1 and GT4 patients with cirrhosis or advanced fibrosis: A real practice analysis from a large regional database in Tuscany, Italy
- Author
-
Francesco Menichetti, Elena Gianni, Filippo Oliveri, Paolo Forte, Al Zignego, Rodolfo Sacco, D. Aquilini, C. Catalani, S. Luchi, A. De Luca, Elena Salomoni, Silvia Chigiotti, Cesira Nencioni, Maurizia Rossana Brunetto, Dario Bartolozzi, Danilo Tacconi, Pierluigi Blanc, Piero Colombatto, S. Sani, Laura Gragnani, and Paola Carrai
- Subjects
Pediatrics ,medicine.medical_specialty ,Cirrhosis ,Hepatology ,business.industry ,Gastroenterology ,medicine ,medicine.disease ,Intensive care medicine ,business ,Advanced fibrosis - Published
- 2016
21. HCV–Related Mixed Cryoglobulinemia: Data from Piter, a Nationwide Italian HCV Cohort Study
- Author
-
M. Puoti, M. Borghi, Alfredo Alberti, Marco Massari, Silvia Fargion, B. Stagno, L Surace, Teresa Santantonio, Roberto Filomia, L. Fucili, Floriano Rosina, Le Weimer, Carlo Ferrari, Em Erne, Carmine Coppola, S. Madonia, A. Di Leo, Alessia Ciancio, Giovanni Raimondo, Monica Monti, Maurizia Rossana Brunetto, O. Patti, Andrea Iannone, G. B. Gaeta, Salvatore Petta, G. Nardone, Pierluigi Blanc, Fp Russo, M. Rumi, María Isabel Colombo, Gabriella Verucchi, M. Andreoni, A. Mallano, Stefano Vella, Maria Cristina Vinci, F. Baldelli, Antonio Benedetti, Erica Villa, Marcello Persico, Liliana Chemello, Loreta A. Kondili, F Giuseppe, Al Zignego, P. Andreone, Gloria Taliani, Luchino Chessa, M. Strazzabosco, Antonio Gasbarrini, Giuseppe Mazzella, Mario U. Mondelli, Elisa Biliotti, Alessandra Orlandini, M. Massella, D. Ieluzzi, Antonio Craxì, and Guglielmo Borgia
- Subjects
030203 arthritis & rheumatology ,03 medical and health sciences ,medicine.medical_specialty ,0302 clinical medicine ,Hepatology ,business.industry ,Internal medicine ,Mixed cryoglobulinemia ,Medicine ,030211 gastroenterology & hepatology ,business ,Cohort study - Published
- 2016
22. PATIENTS WITH MIXED CRYOGLOBULINEMIA AND HCV INFECTION, IN PRESENCE OR ABSENCE OF AUTOIMMUNE THYROIDITIS, HAVE HIGH SERUM LEVELS OF (CXC MOTIF) LIGAND (CXCL)9 AND CXCL11 CHEMOKINES
- Author
-
Alessandro Antonelli, Andreina Teresa Manfredi, Silvia Martina Ferrari, Silvia Frascerra, M Maccheroni, Clodoveo Ferri, Al Zignego, Marco Centanni, Michele Colaci, Alda Corrado, Domenico Sansonno, and Poupak Fallahi
- Subjects
hepatitis c ,thyroiditis ,cxcl9 ,mixed cryoglobulinemia ,cxcl11 ,cxcl10 ,cryoglobulinemia ,autoimmune thyroiditis ,chemokines ,Chemokine ,biology ,business.industry ,Immunology ,High serum ,HCV ,lcsh:R ,lcsh:Medicine ,medicine.disease ,Virology ,Cryoglobulinemia ,Autoimmune thyroiditis ,Mixed cryoglobulinemia ,parasitic diseases ,biology.protein ,Immunology and Allergy ,Medicine ,CXCL11 ,chemokines, HCV, cryoglobulinemia ,business - Abstract
No data are present in the literature regarding chemokine (CXC motif) ligand (CXCL)9 and CXCL11 circulating levels in cryoglobulinemia associated with hepatitis C (MC+HCV), in presence/absence of autoimmune thyroiditis (AT). Serum CXCL9 and CXCL11 have been measured in 38 MC+HCV patients without AT (MCo), 38 MC+HCV patients with AT (MC+AT), and in matched controls without (control 1) or with thyroiditis (control 2). Serum CXCL9 and CXCL11 were significantly higher: in control 2 than control 1 ( p
- Published
- 2012
23. A clinico-serological investigation of arthritis in patients with or without cryoglobulinemic syndrome
- Author
-
L. La Civita, Al Zignego, C. Ferri, and P. Fadda
- Subjects
lcsh:Internal medicine ,medicine.medical_specialty ,business.industry ,Hepatitis C virus ,lcsh:R ,lcsh:Medicine ,Arthritis ,medicine.disease ,medicine.disease_cause ,Gastroenterology ,Serology ,Nephropathy ,Rheumatology ,Internal medicine ,Rheumatoid arthritis ,Immunology ,Epidemiology ,medicine ,Polyarthritis ,Liver function ,lcsh:RC31-1245 ,business - Abstract
Objective: To compare the clinico-serological features of arthritis from two HCV+ patient groups characterised by mixed cryoglobulinemia (MC) or chronic hepatitis (CH). Methods: We retrospectively studied 157 MC patients (119 females, mean age 64.8 yrs, range 36-88) and 155 CH patients (103 females, mean age 58.8 yrs, range 30-81). Patients with HBV and/or HIV co-infections and a follow-up shorter than 1 year were excluded. MC was classified according to standard criteria, while CH classification was based on Desmet’s criteria. Results: No differences in epidemiology were demonstrated between the two series of patients. Although significantly prevalent in MC patients, extra-hepatic manifestations including nephropathy, neuropathy, pneumopathy, mixed cryoglobulins, RF positivity and hypocomplementemia were detected in both patient groups. Arthritis was present in 23 CH (15%) and 12 MC (8%) patients. A symmetrical polyarthritis was observed in 87% of 23 CH patients, while cryoglobulinemic arthritis was invariably asymmetrical and pauciarticular. Unlike MC patients, who had a constantly nonerosive arthritis, in 7/23 CH patients arthritis was erosive. Steroids and/or hydroxycloroquine or D-penicillamine were safe and useful in controlling the arthritis over the short-medium time, although clinical response was more evident in MC patients. Instead, in 5/23 CH and 3/12 MC patients, interferon-alpha treatment was able to trigger or exacerbate the arthritis despite a good control of liver function. Conclusions: HCV infection seems to be, possibly in genetically predisposed patients, responsible for arthritis at times similar to rheumatoid arthritis. In these patients a careful assessment of the interferon-alpha treatment is mandatory owing to the potential ‘arthritogenic effect’ due to its immunoregulatory properties.
- Published
- 2011
24. Preliminary classification criteria for the cryoglobulinaemic vasculitis
- Author
-
Maria Teresa Mascia, Franca Soldano, A. G. Tzioufas, Armando Gabrielli, S. De Vita, Serge Steinfeld, Salvatore Scarpato, M. Lenzi, Cesare Mazzaro, G. F. Ferraccioli, M. Ramos Casals, Stefano Bombardieri, G. De Marchi, M. Pietrogrande, Michael Voulgarelis, Clodoveo Ferri, Patrice Cacoub, Giuseppe Monti, Francesco Saccardo, Antonio Tavoni, L. Corazza, Al Zignego, Peter Lamprecht, Miriam Isola, Luca Quartuccio, Matija Tomšič, Domenico Sansonno, Paolo Fraticelli, Massimo Galli, Pietro Pioltelli, De Vita S, Soldano F, Isola M, Monti G, Gabrielli A, Tzioufas A, Ferri C, Ferraccioli GF, Quartuccio L, Corazza L, De Marchi G, Ramos Casals M, Voulgarelis M, Lenzi M, Saccardo F, Fraticelli P, Mascia MT, Sansonno D, Cacoub P, Tomsic M, Tavoni A, Pietrogrande M, Zignego AL, Scarpato S, Mazzaro C, Pioltelli P, Steinfeld S, Lamprecht P, Bombardieri S, and Galli M
- Subjects
Adult ,Male ,Questionnaires ,Vasculitis ,medicine.medical_specialty ,Settore MED/16 - REUMATOLOGIA ,cryglobulinemia ,Immunology ,Sensitivity and Specificity ,General Biochemistry, Genetics and Molecular Biology ,Cryoglobulins ,Group B ,vasculti ,Pooling data ,Rheumatology ,Internal medicine ,Surveys and Questionnaires ,medicine ,Immunology and Allergy ,Humans ,Cryoglobulinaemic vasculitis ,Aged ,Core set ,business.industry ,classification criteria ,mixed cryoglobulinaemia ,cryoglobulinaemic vasculitis ,Syndrome ,Middle Aged ,medicine.disease ,Cryoglobulinemia ,Criteria ,Surgery ,Positive response ,Multicenter study ,Female ,business - Abstract
Background To develop preliminary classifi cation criteria for the cryoglobulinaemic syndrome or cryoglobulinaemic vasculitis (CV). Methods Study part I developed a questionnaire for CV to be included in the formal, second part (study part II). Positivity of serum cryoglobulins was defi ned by experts as an essential condition for CV classifi cation. In study part II, a core set of classifi cation items (questionnaire, clinical and laboratory items, as agreed) was tested in three groups of patients and controls—that is, group A (new patients with the CV), group B (controls with serum cryoglobulins but lacking CV) and group C (controls without serum cryoglobulins but with features which can be observed in CV). Results In study part I (188 cases, 284 controls), a positive response to at least two of three selected questions showed a sensitivity of 81.9% and a specifi city of 83.5% for CV. This questionnaire was employed and validated in study part II, which included 272 patients in group A and 228 controls in group B. The fi nal classifi cation criteria for CV, by pooling data from group A and group B, required the positivity of questionnaire plus clinical, questionnaire plus laboratory, or clinical plus laboratory items, or all the three, providing a sensitivity of 88.5% and a specifi city of 93.6% for CV. By comparing data in group A versus group C (425 controls), the same classifi cation criteria showed a sensitivity 88.5% and a specifi city 97.0% for CV. Conclusion Classifi cation criteria for CV were developed, and now need validation.
- Published
- 2011
25. HCV-related autoimmune and neoplastic disorders: the HCV syndrome
- Author
-
Al Zignego, Marco Sebastiani, Clodoveo Ferri, D Ferrari, Alessandro Antonelli, Maria Teresa Mascia, Sa Pileri, Poupak Fallahi, Ferri C, Antonelli A, Tascia MT, Sebastiani M, Fallahi P, Ferrari D, Pileri SA, and Zignego AL.
- Subjects
Hepatitis C virus ,Lymphoproliferative disorders ,medicine.disease_cause ,autoimmune disorders ,Autoimmunity ,Autoimmune Diseases ,medicine ,Humans ,HCV ,Hepatology ,business.industry ,Liver Neoplasms ,Gastroenterology ,Autoantibody ,Hepatitis C ,Syndrome ,medicine.disease ,Cryoglobulinemia ,digestive system diseases ,Lymphoproliferative Disorders ,Chronic infection ,Cryoglobulinemia, Hepacivirus, Cryoglobulinemic vasculitis ,Immunology ,business ,Systemic vasculitis - Abstract
Hepatitis C virus (HCV) chronic infection may be associated with a great number of both hepatic and extrahepatic manifestations. HCV lymphotropism is responsible for poly-oligoclonal B-lymphocyte expansion, which is the common underlying alteration in a significant percentage of HCV-infected individuals. The consequent production of different autoantibodies and immune-complexes, including cryoglobulins, may lead to organ- and non-organ-specific immunological alterations. Mixed cryoglobulinemia, a small-vessel systemic vasculitis, is characterized by the coexistence of autoimmune and lymphoproliferative alterations; therefore, it represents the prototype of HCV-associated disorders. Moreover, HCV shows an oncogenic potential; several studies support its pathogenetic link with some malignancies, mainly hepatocellular carcinoma and B-cell lymphomas. On the whole, HCV-related disorders present a heterogeneous geographical distribution, suggesting a role of other important genetic and/or environmental cofactors. While the majority of HCV-infected individuals is asymptomatic or may develop only liver manifestations, a significant percentage of them may develop a variable combination of autoimmune lymphoproliferative disorders. The resulting multiform clinico-pathological condition can be termed HCV syndrome. The natural history of HCV syndrome is the expression of multifactorial and multistep pathogenetic process, which usually proceeds from mild, often isolated manifestations to systemic immune-mediated disorders, and less frequently to overt malignancies.
- Published
- 2007
26. CXCL10 and CCL2 serum levels in patients with mixed cryoglobulinaemia and hepatitis C
- Author
-
Silvia Frascerra, Clodoveo Ferri, Al Zignego, Fabio Galetta, Alessandro Antonelli, Eleuterio Ferrannini, S M Ferrari, Poupak Fallahi, and Ferdinando Franzoni
- Subjects
Male ,Vasculitis ,medicine.medical_specialty ,Hepatitis C virus ,chemokines ,CCL2 ,medicine.disease_cause ,Gastroenterology ,immune system diseases ,Internal medicine ,medicine ,CXCL10 ,Humans ,In patient ,Chemokine CCL2 ,Aged ,mixed cryoglobulinaemia ,hepatitis C virus ,Mixed cryoglobulinaemia ,Hepatology ,business.industry ,Case-control study ,Hepatitis C ,Middle Aged ,medicine.disease ,Chemokine CXCL10 ,Cryoglobulinemia ,Case-Control Studies ,Immunology ,Female ,business - Abstract
No study evaluates serum levels of CXCL10 and CCL2 chemokines in patients with hepatitis C associated mixed cryoglobulinaemia.To measure circulating CXCL10 and CCL2 in cryoglobulinaemic patients.Serum CXCL10 and CCL2 were assayed in 70 consecutive cryoglobulinaemic patients, and in 2 control groups (1:1, gender- and age-matched) of healthy (controls), or of chronic hepatitis C subjects without cryoglobulinaemia.Cryoglobulinaemic patients showed higher CXCL10 serum levels than controls (p0.0001), or hepatitis C patients (p=0.001) (389 +/- 141, 91 +/- 51, 311 +/- 142 pg/ml, respectively). By defining a "high CXCL10" as a value at least 2 S.D. above the mean value of the control group (193 pg/ml), 79% of cryoglobulinaemic patients, 5% of the controls and 69% of hepatitis C patients had high CXCL10 (p0.0001). CXCL10 levels were (p0.01) increased in cryoglobulinaemic patients with active vasculitis, with respect to those without (445+/-108, 339 +/- 161 pg/ml, respectively). Cryoglobulinaemic patients showed significantly higher CCL2 serum level than controls (p0.01), but not than hepatitis C patients (541 +/- 493, 387 +/- 173 and 451 +/- 281 pg/ml, respectively).Our study first demonstrates high serum levels of CXCL10 and CCL2 chemokines in cryoglobulinaemic patients. Circulating CXCL10 is higher overall in cryoglobulinaemic patients with active vasculitis, suggesting a prevalence of the Th1 immune response in this phase.
- Published
- 2007
27. OP0274 Cryoglobulinemic Vasculitis and Primary sjögren's Syndrome are Independent Risk Factors for Lymphoma in a Large Worldwide Population of Patients with Positive Serum Cryoglobulins
- Author
-
Patrice Cacoub, Giuseppe Monti, S. De Vita, Carlo Salvarani, Antonio Tavoni, Al Zignego, Dimitrios Vassilopoulos, Clodoveo Ferri, Patrizia Scaini, Domenico Sansonno, Salvatore Scarpato, Manuel Ramos-Casals, Benjamin Terrier, C. Koutsianas, Luca Quartuccio, Gianfranco Ferraccioli, Gaafar Ragab, Matija Tomšič, M. Pietrogrande, A. G. Tzioufas, Armando Gabrielli, Elisa Gremese, Paolo Fraticelli, Soledad Retamozo, L. Corazza, Stefano Bombardieri, Massimo Galli, Davide Filippini, Loïc Guillevin, M. Voulgarelis, Norihiro Nishimoto, and Francesco Saccardo
- Subjects
medicine.medical_specialty ,education.field_of_study ,business.industry ,Hepatitis C virus ,Immunology ,Population ,medicine.disease ,medicine.disease_cause ,Gastroenterology ,General Biochemistry, Genetics and Molecular Biology ,Cryoglobulins ,Rheumatology ,Lymphoma ,Internal medicine ,Immunology and Allergy ,Medicine ,Sjogren s ,Risk factor ,business ,education ,Cryoglobulinemic vasculitis - Abstract
Background Serum cryoglobulins (SC) may be found in many diseases (1), and the presence of serum cryoglobulins is a known risk factor for lymphoma evolution in some non malignant diseases. Objectives The aim of this study was to distiguish the role of cryoglobulinemic vasculitis (CV), classified according to the recent validated criteria (1,2), and primary Sjogren9s syndrome (pSS) as risk factors of lymphoma in patients positive serum cryoglobulins. Importantly, SC, CV and pSS may occur together. Methods 950 charts from consecutive patients with positive SC were evaluated. Patients carrying both pSS and HCV infection, as well as incomplete charts, were excluded. Results 657 patients with SC were selected, 374 with CV and 283 without CV, according to the published criteria (2,3). PSS, classified according to the American-European Group Criteria was present in 96 patients (44 with CV, 52 without). Lymphoma was reported in 61/657 (9.8%) patients with SC. Among them, CV was present in 44/61 (72,1%; 14 also with pSS), and pSS in 17/61 (27,9%; and 14/17 had CV). Patients with SC with CV showed an higher prevalence of lymphoma than patients with SC without CV (44/374, 11.5% vs.17/283, 6.3%; p=0.025, OR=1.93 [95%IC: 1.08-3.39]. Patients with pSS, SC and CV also showed a higher prevalence of lymphoma than patients with pSS, SC but without CV (14/44, 31.8% vs. 3/52, 7.4%; p=0.001, OR=7.62 [95%CI 2.02-28.74]. CV and pSS were confirmed as independent risk factor for lymphoma by multivariate analysis (OR 2,18 95%CI 1,18-3,83, p=0,012; OR 2,65 95%CI 1,04-6,76, p=0,042, respectively). Infection by the hepatitis C virus (HCV) was detected in 467/561 (83,2%) patients with SC without pSS, and did not statistically predispose to lymphoma when associated with CV in this subset (p=1,0). Conclusions Cryoglobulinemic vasculitis and pSS are independent risk factors for lymphoma in patients with evidence of SC. Patients with both the conditions (CV and pSS) have the highest risk. In the follow-up of SC positive patients, a very high attention should be deserved to pSS, in particular when CV is present. References De Vita S, et al. Ann Rheum Dis. 2011; 2) Quartuccio L, et al. Rheumatology (Oxford). 2014 Disclosure of Interest None declared
- Published
- 2015
28. O060 : MIR-17/92 expression pattern: A molecular signature of HCV-related mixed cryoglobulinemia
- Author
-
T. Urraro, Al Zignego, Alessia Piluso, Monica Monti, A. Genovesi, and Laura Gragnani
- Subjects
Pathology ,medicine.medical_specialty ,Hepatology ,business.industry ,media_common.quotation_subject ,Hypervascularity ,medicine.disease ,Liver disease ,Expression pattern ,Mixed cryoglobulinemia ,medicine ,Contrast (vision) ,business ,media_common - Abstract
s / Digestive and Liver Disease 47S (2015) e1–e18 e13 escape the demonstration of arterial hypervascularity, CEUS must be performed immediately after conventional US to contrast the malignant fate of small lesions arising in cirrhotics. http://dx.doi.org/10.1016/j.dld.2015.01.030
- Published
- 2015
29. P0752 : NOTCH4 and MHC class II polymorphisms contibute to HCV-related benign and malignant lymphoproliferative diseases
- Author
-
Alessia Piluso, A. Genovesi, Laura Gragnani, Al Zignego, Massimo Libra, and V. De Re
- Subjects
MHC class II ,Hepatology ,biology ,business.industry ,Immunology ,biology.protein ,Medicine ,business - Published
- 2015
30. Mir-17/92 expression pattern: A molecular signature of HCV-related mixed cryoglobulinemia
- Author
-
Laura Gragnani, Alessia Piluso, Monica Monti, Al Zignego, A. Genovesi, Elisa Fognani, and T. Urraro
- Subjects
Hepatology ,Expression pattern ,business.industry ,Mixed cryoglobulinemia ,Gastroenterology ,Cancer research ,Medicine ,Signature (topology) ,business - Published
- 2015
31. Analysis of interleukin (IL)-1beta IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders
- Author
-
Libra M, Mangano K, Anzaldi M, Quattrocchi C, Donia M, di Marco R, Signorelli S, Scalia G, Al, Zignego, VALLI DE RE, Mc, Mazzarino, and Nicoletti F
- Subjects
Male ,Lymphoma, B-Cell ,Genotype ,Sialoglycoproteins ,Receptors, Interleukin-1 ,Non-Hodgkin's lymphoma ,Hepacivirus ,Hepatitis C, Chronic ,Middle Aged ,Interleukin-1 ,Mixed cryoglobulinemia syndrome ,Interleukin 1 Receptor Antagonist Protein ,Cryoglobulinemia ,Case-Control Studies ,Leukocytes, Mononuclear ,Humans ,RNA, Viral ,Female ,Receptors, Interleukin-1 Type II ,Interleukin-1 Receptor Accessory Protein - Abstract
Hepatitis C virus (HCV) causes hepatitis, liver cirrhosis and hepatocellular carcinoma, and may also induce type II mixed cryoglobulinemia syndrome (MC), a disease characterized by clonal B-cell lymphoproliferations that can evolve into non-Hodgkin's lymphoma (NHL). Interleukin-1 (IL-1) is a cytokine that plays an important role in initiating the cascade of events of immunoinflammatory responses through costimulation of T lymphocytes, B-cell proliferation, induction of adhesion molecules and stimulation of the production of other inflammatory cytokines. The role of IL-1 in immunoinflammatory responses is highlighted by the presence of endogenous regulators (IL-1 receptor antagonist, soluble receptors type 1 and II, human IL-1 accessory protein) that, when secreted into the blood stream may serve as endogenous regulators of IL-1 action. The aim of this study was to evaluate whether abnormalities in the blood levels of IL-1beta IL-1 receptor antagonist, soluble IL-1 receptor type II and human IL-1 accessory protein in HCV+ patients are associated with development of MC and/or NHL. Relative to healthy controls, we observed: i) an increase in the circulating levels of IL-1beta in HCV+ patients simultaneously affected by NHL; ii) increased levels of IL-1 accessory protein in patients singly infected by HCV; iii) increase of IL-1 receptor antagonist in HCV+ patients and in those affected also by NHL with or without MC; iv) a homogeneous increase of sIL-1R type II in all the subgroup of patients. These data indicate that an attempt to increased circulating levels of IL-1 inhibitors occurs at different extent in the course of HCV infection as well as in its progression to NHL and/or MC.
- Published
- 2006
32. 454 microRNA PROFILE MODIFICATIONS IN HEPATITIS C VIRUS-RELATED MIXED CRYOGLOBULINEMIA
- Author
-
Elisa Fognani, P. Caini, Al Zignego, J. Ranieri, T. Urraro, Giacomo Laffi, Monica Monti, Laura Gragnani, Carlo Giannini, Alessia Piluso, and E. Triboli
- Subjects
Hepatology ,business.industry ,Hepatitis C virus ,Mixed cryoglobulinemia ,Medicine ,MicroRNA Profile ,business ,medicine.disease_cause ,Virology - Published
- 2013
33. F-41 Mixed cryoglobulinemia syndrome is a negative prognostic factor in the standard of care (Peg-IFN+ribavirin) anti-HCV therapy
- Author
-
T. Urraro, Al Zignego, Monica Monti, C. Iannacone, E. Pellegrini, Giacomo Laffi, Carlo Giannini, U. Arena, A. Petrarca, Laura Gragnani, Alessia Piluso, J. Ranieri, E. Triboli, and Elisa Fognani
- Subjects
medicine.medical_specialty ,Prognostic factor ,Standard of care ,Hepatology ,Anti hiv ,business.industry ,Ribavirin ,Gastroenterology ,Virology ,chemistry.chemical_compound ,chemistry ,Internal medicine ,Mixed cryoglobulinemia ,Medicine ,business - Published
- 2012
34. OP0228 Rituximab Monotherapy of Severe Hcv-Related Cryoglobulinemic Vasculitis for More than 2 Years: Follow-Up of A Randomized Controlled Multicentre Study
- Author
-
Stefano Bombardieri, Massimo Galli, Al Zignego, S. De Vita, Paolo Fraticelli, Luca Quartuccio, Patrizia Scaini, L. Corazza, F. Zuliani, Salvatore Scarpato, Cesare Mazzaro, M. Lenzi, T. Urraro, Dario Roccatello, Pietro Pioltelli, Armando Gabrielli, Roberta Zani, Clodoveo Ferri, Davide Filippini, Oreste Perrella, Giuseppe Monti, Marco Sebastiani, Costanza Sbreglia, Francesco Saccardo, Simone Baldovino, M. Pietrogrande, and Antonio Tavoni
- Subjects
Pediatrics ,medicine.medical_specialty ,business.industry ,Immunology ,Arthritis ,medicine.disease ,General Biochemistry, Genetics and Molecular Biology ,law.invention ,Hypogammaglobulinemia ,Regimen ,Rheumatology ,Maintenance therapy ,Randomized controlled trial ,law ,medicine ,Immunology and Allergy ,Rituximab ,Adverse effect ,business ,Cryoglobulinemic vasculitis ,medicine.drug - Abstract
Background Two independent controlled randomized trials demonstrated the efficacy and safety of rituximab (RTX) monotherapy in severe cryoglobulinemic vasculitis (CV) (1, 2), with one reporting a prolonged follow-up (1). Objectives To report the very long term efficacy and safety of RTX monotherapy in severe CV since a regimen of RTX monotherapy was maintained after the end of the abovementioned trial (1). Methods Long term follow up data of a trial of RTX in severe CV (1) were analysed. During this follow-up, only RTX monotherapy was used. Disease activity at the last follow-up visit, adverse events and survival were registered. Clinical response was evaluated at the last follow-up visit, and was scored as follows: i) complete remission (no activity), partial remission (response >50% of at least one manifestation among glomerulonephritis, severe neuropathy or skin ulcers) (1), and active disease. Results After the end of the 2-year controlled trial (1), follow-up data were available in 36 patients undergoing RTX, all HCV positive. The mean follow up after the beginning of RTX therapy (1) was 70.22±20.41 months, including 29 patients followed for more than 4 years (78.4±12.6 months) and 7 patients followed for 2.4-4 years (36.4±6 months). Of them, 3 patients were lost from follow-up shortly after the end of the trial, and 9 patients died. Of the remaining 24 patients, 14/24 (58.3%) showed complete clinical remission at the last follow-up, 6/24 (25%) a partial remission, while 4/24 (16.7%) had an active disease. A first repeated RTX course (1 g two weeks apart) was required in 50% of the patients (12/24), while 25% of the patients (6/24) needed more than one course, for a total of 19 retreatments. Patients were retreated for nephritis (7/19), neuropathy (6/19), skin ulcers (7/19) or diffuse purpura (6/19). Three patients underwent a maintenance RTX regimen, all with 1 g × 2 every 6 months, with a complete and partial remission at the last follow-up noticed in 2/3 and 1/3, respectively. Recurrent infections occurred only in three patients (8%; urinary and upper respiratory), and they were related to persistent hypogammaglobulinemia in 2/3. Death occurred in 9 patients, all showing persistent active disease. Conclusions A long-term RTX therapy lasting several years is effective and safe in about two thirds of the patients with severe CV. The advantage of retreatment at relapse regimen instead of a maintenance therapy, and whether this may occur in a further subset of patients, needs further investigation. References De Vita S, et al. Arthritis Rheumatol. 2012;64(3):843-53. Sneller MC, et al. Arthritis Rheumatol. 2012;64(3):835-42. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.3872
- Published
- 2014
35. P1158 EFFICACY AND SAFETY OF BOCEPREVIR-BASED THERAPY IN HCVG1 TREATMENT-EXPERIENCED PATIENTS WITH ADVANCED FIBROSIS/CIRRHOSIS: THE ITALIAN AND SPANISH NPP EARLY ACCESS PROGRAM
- Author
-
Javier Crespo, B. Ruiz Antoran, Xavier Forns, Patrick Maisonneuve, J.L. Calleja, I. Fermandez, C. Fernández-Rodríguez, J. de la Revilla, Francesco Mazzotta, Sergio Babudieri, Maurizio Russello, Juan Manuel Pascasio, Carlo Magni, Al Zignego, F. Gea, A. Licata, Ramón Pérez-Álvarez, Maximino Delgado, Savino Bruno, Massimo Zuin, T. Santantonio, M. Rizzetto, Alfredo Alberti, Alberto Colombo, J.M. Navarro, Joaquín Arenas, V. Di Marco, C. Colletta, F. Farina, Maurizio Koch, Simona Bollani, Sara Piovesan, M. Caremani, Mario Pirisi, Manuel Romero-Gómez, Marco Massari, Rafael Bárcena, J.R. Larrubia, Antonio Craxì, A. Ciancio, and Alessandra Mangia
- Subjects
medicine.medical_specialty ,Cirrhosis ,Hepatology ,business.industry ,Hepatitis C ,medicine.disease ,Advanced fibrosis ,Treatment experienced ,chemistry.chemical_compound ,chemistry ,Boceprevir ,Medicine ,business ,Intensive care medicine - Published
- 2014
36. Efficacy and safety of Boceprevir-based therapy in HCVG1 treatment-experienced patients with advanced fibrosis/cirrhosis: Italian NPP survey
- Author
-
Al Zignego, Marco Massari, E. Marchionne, A. Traverso, Luigi Muratori, V. Di Marco, Alberto Colombo, Simona Landonio, Gaetano Serviddio, Valeria Piazzolla, A. Moretti, Sergio Babudieri, A. Licata, Alessia Ciancio, Massimo Zuin, Francesco Mazzotta, Mario Rizzetto, Maurizio Russello, Teresa Santantonio, S. Fangazio, L. Cavalletto, Simona Bollani, Vincenza Calvaruso, F. Farina, C. Colletta, Antonio Craxì, Carlo Magni, Savino Bruno, Sara Piovesan, M. Caremani, and Alessandra Mangia
- Subjects
medicine.medical_specialty ,Hepatology ,business.industry ,Infectious disease (medical specialty) ,Family medicine ,Gastroenterology ,medicine ,business ,Treatment experienced ,Advanced fibrosis - Abstract
S. Bruno1, S. Bollani1, A.L. Zignego2, V. Calvaruso3, C. Magni4, S. Landonio4, M. Rizzetto5, A. Ciancio5, A. Mangia6, V. Piazzolla6, M. Caremani7, S. Piovesan8, L. Cavalletto9, S. Babudieri9, A. Moretti 10, C. Colletta11, M. Massari12, S. Fangazio13, F. Mazzotta14, L. Muratori15, A.E. Colombo16, M. Zuin17, A. Traverso18, T. Santantonio19, F. Farina20, E. Marchionne21, G. Serviddio22, M. Russello23, A. Licata24, A. Craxi3, V. Di Marco3 1 Internal Medicine, AO Fatebenefratelli e Oftalmico, Milano, Italy 2 Internal Medicine, Universita di Firenze, Italy 3 Gastroenterology, Universita di Palermo, Italy 4 Infectiuos Diseases, Ospedale Sacco, Milano, Italy 5 Gastroenterology, Universita di Torino, Turin, Italy 6 Liver Unit, IRCCS Casa del Sollievo e della Sofferenza, San Giovanni Rotondo, Italy 7 Infectious Diseases, Azienda Ospedaliera, Arezzo, Italy 8 Internal Medicine, Universita di Padova, Italy 9 Infectious Disease, Universita di Sassari, Italy 10 Gastroenterology, San Filippo Neri, Roma, Italy 11 Internal Medicine, COQ Ospedale Madonna del Popolo, Omegna, Italy 12 Infectious Diseases, IRCCS – ASMN Reggio Emilia, Italy 13 Internal Medicine, Universita di Novara, Italy 14 Infectious Diseases, Azienda Ospedaliera, Siena, Italy 15 Internal Medicine, Universita di Bologna, Italy 16 Gastroenterology, Ospedale S. Anna, Como, Italy 17 Internal Medicine, Universita di Milano, Italy 18 Infectious Disease, AOU, Parini, Aosta, Italy 19 Infectious Diseases, Universita di Foggia, Italy 20 Infectious Diseases, Ospedale Ca Foncello, Treviso, Italy 21 Infectious Diseases, AOU Ospedali Riuniti, Ancona, Italy 22 Internal Medicine, Universita di Foggia, Italy 23 Liver Unit, ARNAS Garibaldi, Catania, Italy 24 Liver Unit, Universita di Palermo, Italy
- Published
- 2014
37. Dysregulation of microRNA expression in PBMCs from patients with HCV-related malignancies
- Author
-
Mauro Bernardi, Laura Gragnani, Al Zignego, Elisa Fognani, Barbara Boldrini, T. Urraro, Giacomo Laffi, P. Andreone, Monica Monti, Alessia Piluso, E. Grandini, and P. Caini
- Subjects
Hepatology ,business.industry ,microRNA ,Gastroenterology ,Cancer research ,Medicine ,business ,Peripheral blood mononuclear cell - Published
- 2014
38. 701 HOST GENETIC DETERMINANTS IN HCV-RELATED MIXED CRYOGLOBULINEMIA
- Author
-
Elisa Fognani, Alessia Piluso, Monica Monti, J. Ranieri, Al Zignego, Giacomo Laffi, P. Caini, Carlo Giannini, A. Petrarca, and Laura Gragnani
- Subjects
Hepatology ,Host (biology) ,Mixed cryoglobulinemia ,Biology ,Virology - Published
- 2010
39. 878 HCV-RELATED MIXED CRYOGLOBULINEMIA AND BAFF PROMOTER POLYMORPHISM
- Author
-
Monica Monti, Laura Gragnani, Carlo Giannini, A. Petrarca, P. Caini, Alessia Piluso, Al Zignego, and Giacomo Laffi
- Subjects
Hepatology ,Immunology ,Mixed cryoglobulinemia ,Promoter polymorphism ,Biology ,B-cell activating factor - Published
- 2009
40. OP0186 Etiological therapy in HCV-related mixed cryoglobulinemia syndrome: The role of IL28B genotype as predictor of response
- Author
-
E. Triboli, Carlo Giannini, A. Petrarca, Al Zignego, J. Ranieri, E. Pellegrini, Giacomo Laffi, Elisa Fognani, P. Caini, Alessia Piluso, Laura Gragnani, T. Urraro, and Monica Monti
- Subjects
business.industry ,Hepatitis C virus ,Immunology ,Lymphoproliferative disorders ,Hepatitis C ,Odds ratio ,medicine.disease ,medicine.disease_cause ,humanities ,General Biochemistry, Genetics and Molecular Biology ,Rheumatology ,Genotype ,medicine ,Etiology ,Immunology and Allergy ,Allele ,business ,Systemic vasculitis - Abstract
Background Mixed cryoglobulinemia syndrome (MCS) is a HCV-related, invalidating lymphoproliferative disorder (LPD) whose manifestations are related to a systemic vasculitis. The pathogenesis of MCS is a multistep process involving a strong and sustained B-cell proliferation and genetic events on the basis of host predisposing factors [1]. Standard of care (SOC: PegIFN+RBV) anti-HCV therapy is now the first therapeutic option in HCV+ MCS, however, due to its side effects, the therapeutic decision is often difficult, especially in MCS patients with HCV-G1/4 [2]. Consequently, the possibility to better predict the therapy outcome would be precious. In hepatitis C, genetic variations in the IL28B gene, are strongly associated with the response to anti-HCV therapy [3]. Nowadays, IL28B polymorphisms in HCV-related MCS has been never investigated and it is not possible to exclude that the complex modifications of the immune system characterizing MCS could modify its predictive value. Objectives The aim of this study was to evaluate the role of IL28B genotype in influencing the response to IFN-based treatment and in predisposing to MCS. Methods The IL28B polymorphism was investigated by using allele-specific real-time PCR tecniques in 515 HCV-positive patients: 267 with MCS and 248 without MCS or any LPD (controls). Results A comparable distribution of the IL28B alleles (rs12979860/rs8099917) for HCV-positive patients with and without MCS was recorded, suggesting that this polymorphism do not play a major role in conditioning MCS evolution. Among the 267 HCV-MCS, 123 patients completed a SOC anti-HCV treatment and at least 24 weeks of follow-up. A significant correlation between IL28B major allele homozygosis and MCS response was observed (p=0.0021); the clinical response almost coincided with the virological one. The logistic regression analysis defined the IL28B genotype as a strong independent predictor of MCS response (p=0.0069, odds ratio 6.11; C.I. 1.58-21.22). According to HCV genotype, the predictive value was limited to the most frequent and difficult-to-treat HCV genotypes. Conclusions For the first time, we showed that in HCV-G1/4-MCS patients, IL28B genotype is an useful predictor of response to IFN-based therapy. This would greatly help in the management of this difficult category of HCV patients. This study also suggests that IL28B genotype do not influence the evolution of HCV infection to MCS References Zignego AL, Giannini C, Ferri C: Hepatitis C virus-related lymphoproliferative disorders: an overview. World J Gastroenterol 2007, 13:2467-2478. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011, 55:245-264. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401 Disclosure of Interest None Declared
- Published
- 2013
41. SAT0175 Results of the Classification Criteria for Cryoglobulinemic Vasculitis Validation Study
- Author
-
M. M. El Menyawi, V. Conteduca, Al Zignego, G. F. Ferraccioli, Manuel Ramos-Casals, Matija Tomšič, Miriam Isola, T. Urraro, Massimo Galli, Luca Quartuccio, M. Voulgarelis, A. Ghinoi, Davide Filippini, Benjamin Terrier, Francesco Saccardo, Cesare Mazzaro, Elisa Gremese, Paolo Fraticelli, E Catarsi, Carlo Salvarani, Patrice Cacoub, Domenico Sansonno, Mohamed Nabil Salem, Norihiro Nishimoto, Marco Sebastiani, C. Koutsianas, Naguib Zoheir, Nicolò Pipitone, L. Corazza, Clodoveo Ferri, A. G. Tzioufas, Armando Gabrielli, Loïc Guillevin, Gaafar Ragab, M. Pietrogrande, Patrizia Scaini, Soledad Retamozo, Antonio Tavoni, Dimitrios Vassilopoulos, Stefano Bombardieri, Giuseppe Monti, Pietro Pioltelli, and S. De Vita
- Subjects
Validation study ,medicine.medical_specialty ,business.industry ,Immunology ,medicine.disease ,Cryoglobulinemia ,General Biochemistry, Genetics and Molecular Biology ,Cryoglobulins ,Group B ,Rheumatology ,Sample size determination ,Internal medicine ,Cohort ,Immunology and Allergy ,Rheumatoid factor ,Medicine ,business ,Cryoglobulinemic vasculitis - Abstract
Background the preliminary Classification Criteria for cryoglobulinemic vasculitis (CV) have been developed in 2011 by an European cooperative study (1). Objectives to validate these Classification Criteria for CV with the participation of non-European Countries. Methods 20 Centres from Europe, Egypt, and Japan partecipated. New consecutive, unselected patients with CV (Group A) and controls (subjects with cryoglobulins without a CV based on the golden standard clinical judgment; Group B) were studied. A sample size of 140 patients for each group was estimated to obtain a sensitivity (SE) and a specificity (SP) of at least 90±5%, according to the previous results (1). A dedicated chart was distributed to the Centres. The sensitivity and specificity of the 2011 Classification Criteria were calculated in the present validation series by comparing Group A versus Group B. Results 251 patients in Group A and 175 controls in Group B were recruited. The questionnaire (at least 2/3 positive answers) showed a SE of 89.2% (95% CI 85.4-93.1) and a SP of 93.7% (95% CI 90.1-97.3); the clinical item (at least 3/4 clinical items among constitutional, articular, vascular and neurologic involvement) showed a SE of 76.1% (95% CI 70.8-81.4) and a SP of 88.6% (95% CI 83.8-93.9), and the laboratory item (at least 2/3 tests, among positive rheumatoid factor, low C4, and the presence of serum monoclonal component) showed 75.1% (95% CI 69.5-80.7) of SE and 71.5% (95% CI 64.6-78.4) of SP. The final 2011 Classification Criteria (at least 2/3 positive items) showed a SE of 89.3% (95% CI 85.3-93.3) and a SP of 93.9 % (95% CI 90.3-97.6). Conclusions: Conclusion : The 2011 International Classification Criteria for the cryoglobulinemic vasculitis have been validated in a new cohort of real cases and controls. Patients where CV is suspected on clinical grounds, but where cryoglobulins are negative, cannot be classified, since positive serum cryoglobulinemia is a conditio sine qua non for classification (1). However, the performance of these criteria on this subset of patients is under evaluation. References De Vita S, et al. Ann Rheum Dis 2011;70:1183-90. Disclosure of Interest None Declared
- Published
- 2013
42. OC-23 Role of microRNA profile modifications in hepatitis C virus-related mixed cryoglobulinemia
- Author
-
T. Urraro, Monica Monti, Al Zignego, Alessia Piluso, E. Triboli, Giacomo Laffi, Laura Gragnani, Carlo Giannini, P. Caini, J. Ranieri, and Elisa Fognani
- Subjects
Hepatology ,business.industry ,Hepatitis C virus ,Mixed cryoglobulinemia ,Gastroenterology ,medicine ,MicroRNA Profile ,medicine.disease_cause ,business ,Virology - Published
- 2013
43. OC-28 Boceprevir triple therapy in patients with mixed cryoglobulinemia
- Author
-
Alessio Fabbrizzi, Al Zignego, T. Urraro, S. Moscarella, Giacomo Laffi, J. Ranieri, Monica Monti, Carlo Giannini, U. Arena, P. Caini, and E. Triboli
- Subjects
chemistry.chemical_compound ,medicine.medical_specialty ,Hepatology ,chemistry ,business.industry ,Boceprevir ,Internal medicine ,Mixed cryoglobulinemia ,Gastroenterology ,medicine ,In patient ,business - Published
- 2013
44. P.04.1 IL28B POLYMORPHISM IN CHRONIC HBV INFECTION: THE CC ALLELE DOES NOT CORRELATE WITH THE PHASE OF THE INFECTION NOR WITH HBSAG CLEARANCE IN IFN TREATED PATIENTS
- Author
-
Maurizia Rossana Brunetto, Carlo Giannini, Filippo Oliveri, Al Zignego, F. Moriconi, Veronica Romagnoli, Barbara Coco, Daniela Cavallone, Ferruccio Bonino, A. Stabile, Pietro Ciccorossi, B. Cherubini, Piero Colombatto, and C. Rastelli
- Subjects
HBsAg ,Hepatology ,business.industry ,Immunology ,Gastroenterology ,Medicine ,Allele ,business ,Virology ,Il28b polymorphism - Published
- 2012
45. OC.09.3: MODELLING HCV DYNAMICS ACCORDING TO IL28B POLYMORPHISM SHOWS DIFFERENT ANTIVIRAL EFFECTS OF PEGIFNS/RIBAVIRIN AND PROVIDES A NEW ACCURATE TOOL FOR TREATMENT MANAGEMENT
- Author
-
Ferruccio Bonino, Barbara Coco, Carlo Giannini, L. Civitano, F. Moriconi, Pietro Ciccorossi, Maurizia Rossana Brunetto, Al Zignego, C. Rastelli, B. Cherubini, Veronica Romagnoli, Daniela Cavallone, A. Stabile, Piero Colombatto, and Filippo Oliveri
- Subjects
medicine.medical_specialty ,Creatinine ,Hepatology ,medicine.diagnostic_test ,business.industry ,Ribavirin ,Gastroenterology ,Viremia ,medicine.disease ,Virology ,Il28b polymorphism ,Treatment management ,Virological response ,chemistry.chemical_compound ,chemistry ,Internal medicine ,medicine ,Liver function tests ,business ,Blood phosphorus - Abstract
Material and methods: 418 consecutive NUC-naive patients with chronic hepatitis B were recruited in 18 Liver Units in Italy and treated with ETV 0.5 mg for 30 months (2-38). Liver function tests and HBV DNA, assessed by a sensitive assays, were performed every 3 months. Virological breakthrough was defined as >1 log U increase of viremia, a “blip” was the reoccurrence of detectable viremia ( 9.0) and ALT were elevated in 85% of the patients. During ETV treatment, 90% of the patients achieved undetectable HBV DNA: virological response rates were 67%, 86%, 92%, 95% and 96% at month 6, 12, 18, 24, and 30. The corresponding features for ALT normalization were 69%, 81%, 85%, 87% and 93%. After achieving undetectable HBV DNA, few patients had blips of viremia which were not confirmed in the following visits in the vast majority of cases. Primary non response at week 12, partial virological response at week 48 and virological breakthroughs occurred in < 1%, 14% and < 1% of the patients. TDF was added to ETV in 17 patients with partial virological response. Of the 39 partial virologial responders at week 48 not rescued with TDF and followed for additional 6-9 months, only 20 (50%) cleared viremia spontaneously. No major safety issues were reported. Median serum creatinine remained unchanged during treatment: from 0.90 (0.50-9.0) at baseline to 0.90 (0.91 (0.50-8.0) mg/dl at the last visit. A greater than 0.3 or 0.5 mg/dl increase of serum creatinine in the last visit versus baseline occurred in 3% and 0.6% of the patients, respectively. Blood phosphorus levels dropped below 2.3 mg/dl in 1% of the patients. Conclusions: The vast majority of NUC-naive patients treated with ETV monotherapy in field practice achieved and maintained a virological response through 30 months.
- Published
- 2011
46. OC-19 Modelling HCV kinetics by IL28B genotype is a new accurate tool for individual treatment management
- Author
-
Pietro Ciccorossi, Ferruccio Bonino, Carlo Giannini, C. Rastelli, A. Stabile, L. Civitano, Barbara Coco, Al Zignego, Filippo Oliveri, Piero Colombatto, F. Moriconi, B. Cherubini, Veronica Romagnoli, Maurizia Rossana Brunetto, and Daniela Cavallone
- Subjects
Treatment management ,medicine.medical_specialty ,Liver disease ,Hepatology ,business.industry ,Internal medicine ,Gastroenterology ,Medicine ,Il28b genotype ,business ,medicine.disease - Abstract
s of the A.I.S.F. Annual Meeting 2010 /Digestive and Liver Disease 43S (2011), S65–S108 S71
- Published
- 2011
47. P.131 VIRAL KINETICS IN PATIENTS WITH CHRONIC HEPATITIS B TREATED WITH COMBINATION THERAPY WITH PEG-IFN AND NUCLEOSIDE ANALOGUES
- Author
-
G. Elena, A. Farese, R. Puntili, Stefano Milani, F. Bucciero, Cristina Stasi, Al Zignego, Calogero Surrenti, S. Bresci, Giampaolo Corti, E. Lorefice, Paolo Forte, and Carlo Giannini
- Subjects
Hepatology ,Chronic hepatitis ,Combination therapy ,business.industry ,Gastroenterology ,Medicine ,In patient ,business ,Nucleoside ,Virology ,Viral kinetics - Published
- 2010
48. F.N.33 LONG-TERM OUTCOME OF HCV-RELATED MIXED CRYOGLOBULINEMIA IN PATIENTS ACHIEVING SUSTAINED VIRAL RESPONSE (SVR) AFTER ANTIVIRAL THERAPY
- Author
-
Carlo Giannini, A. Petrarca, Monica Monti, Al Zignego, Giacomo Laffi, M. Moneglia, Elisa Fognani, Laura Gragnani, P. Caini, Alessia Piluso, G. Razzolini, and J. Ranieri
- Subjects
Oncology ,medicine.medical_specialty ,Hepatology ,business.industry ,Gastroenterology ,Antiviral therapy ,Outcome (game theory) ,Term (time) ,Internal medicine ,Mixed cryoglobulinemia ,medicine ,Sustained viral response ,In patient ,business - Published
- 2010
49. [630] CAN DEPLETION OF B-CELLS BY ANTI-CD20 MONOCLONAL ANTIBODY IN HCV+ MIXED CRYOGLOBULINEMIA (MC) IMPROVE LIVER CIRRHOSIS?
- Author
-
Al Zignego, A. Bosi, Giacomo Laffi, L. Rigacci, Carlo Giannini, Roberto Caporale, A. Petrarca, and Paolo Montalto
- Subjects
Cirrhosis ,Hepatology ,business.industry ,medicine.drug_class ,Immunology ,Mixed cryoglobulinemia ,medicine ,Anti cd20 ,medicine.disease ,business ,Monoclonal antibody - Published
- 2007
50. 9 Analysis of HCV persistence in patients with sustained virological response
- Author
-
Monica Monti, Vera Solazzo, Al Zignego, P. Caini, U. Arena, Giacomo Laffi, Francesca Giannelli, G. La Villa, Paolo Gentilini, Carlo Giannini, and A. Petrarca
- Subjects
Virological response ,Persistence (psychology) ,Hepatology ,business.industry ,Immunology ,Medicine ,In patient ,business - Published
- 2006
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.